Medication Monitor

Generic Name (Trade Name—Company)
September 25, 2019


(Erleada—Janssen Biotech)
Apalutamide has new indication for metastatic castration-sensitive prostate cancer

FDA approved apalutamide for patients with metastatic castration-sensitive prostate cancer. Apalutamide was initially approved in 2018 for patients with nonmetastatic castration-resistant prostate cancer.

Common adverse reactions are fatigue, arthralgia, rash, decreased appetite, fall, weight loss, hypertension, hot flush, diarrhea, and fracture.

The recommended dose of apalutamide is 240 mg (four 60-mg tablets) orally once daily, with or without food. Patients should also receive a gonadotropin-releasing hormone analog concurrently or should have had bilateral orchiectomy.